TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Aziyo Biologics ( (ELUT) ) is now available.
On November 7, 2025, Elutia Inc., a Delaware corporation, received a notification from Nasdaq regarding its Class A common stock, which had a closing bid price below $1.00 for 30 consecutive business days, risking non-compliance with Nasdaq’s listing requirements. The company has been given a 180-day compliance period to rectify this issue, with potential for an additional 180-day period if necessary. Elutia intends to monitor the situation closely and explore options to maintain its Nasdaq listing, though there is no assurance of compliance.
The most recent analyst rating on (ELUT) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
The overall stock score of 44 reflects significant financial challenges, with negative equity and cash flow issues being the most critical factors. While the earnings call provided some positive strategic developments, the technical analysis and valuation remain weak, contributing to the low score.
To see Spark’s full report on ELUT stock, click here.
More about Aziyo Biologics
Average Trading Volume: 246,058
Technical Sentiment Signal: Sell
Current Market Cap: $36.54M
For detailed information about ELUT stock, go to TipRanks’ Stock Analysis page.